Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hansa Biopharma AB is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions associated with the company's filings. These actions are handled by 2 distinct examiners, meaning each examiner is responsible for one active matter. The workload is divided between 2 distinct art units, suggesting that the company's biological research spans different specialized examination divisions.
KIEFER, DALTON EDWARD is identified as the busiest examiner for the portfolio, with 1 pending office action. This examiner is one of the 2 distinct examiners currently reviewing the company's 2 pending office actions. Since the cases are located in 2 distinct art units, the prosecution strategy should account for the specific procedural nuances of each unit. The data shows a small but distributed pipeline with no concentration of matters under a single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
| MARTIN, RACHEL E | 1 | 54.2% | +54.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710020 | METHODS FOR ENHANCING ADOPTIVE CELL TRANSFER IMMUNOTHERAPIES | KIEFER, DALTON EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710020 | METHODS FOR ENHANCING ADOPTIVE CELL TRANSFER IMMUNOTHERAPIES | KIEFER, DALTON EDWARD | — |
| 18053676 | CYSTEINE PROTEASE | MARTIN, RACHEL E | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710020 | METHODS FOR ENHANCING ADOPTIVE CELL TRANSFER IMMUNOTHERAPIES | KIEFER, DALTON EDWARD | 1652 | §112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18053676 | CYSTEINE PROTEASE | MARTIN, RACHEL E | 1657 | §112 | Non-Final OA | — | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHansa Biopharma AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dalton Edward Kiefer has the most, with 1 of Hansa Biopharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
